Skip to main content
Dosing initiated for hemophilia B genome-editing therapy candidate

The first patient has been dosed for Sangamo Therapeutics' Phase I/II trial to evaluate its genome-editing therapy candidate SB-FIX in patients with severe hemophilia B. The study will assess SB-FIX in 12 participants, who will be given a low, medium or high dose to establish its preliminary effectiveness, safety and tolerability.

Full Story: